Stay updated on Regeneron Pharmaceuticals Press Releases

Sign up to get notified when there's something new on the Regeneron Pharmaceuticals Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Regeneron Pharmaceuticals Press Releases page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    8 days ago
    Change Detected
    Summary
    Important update:The recent change on the webpage indicates that the announcement regarding Regeneron's financial and operating results scheduled for February 2, 2024, has been replaced with news that Dupixent® (dupilumab) has been accepted for FDA Priority Review for the treatment of COPD with Type 2 Inflammation. This update likely represents a significant development in the company's product pipeline and regulatory progress.
    Difference
    15%
    Check dated 2024-02-24T03:30:06.000Z thumbnail image
  7. Check
    10 days ago
    Change Detected
    Summary
    Important update:The recent update on the webpage indicates that the Linvoseltamab BLA for the Treatment of Relapsed/Refractory Multiple Myeloma has been accepted for FDA Priority Review, marking a significant milestone in the drug's regulatory process. This news is likely to be of great interest to users following the development of this treatment, as it signifies progress towards potential approval and availability for patients in need.
    Difference
    4%
    Check dated 2024-02-22T01:08:39.000Z thumbnail image
  8. Check
    15 days ago
    Change Detected
    Summary
    Important update:The value on the webpage has changed to "Feb 16 Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)." This change represents the recent approval of Dupixent® (dupilumab) in Japan for the treatment of Chronic Spontaneous Urticaria (CSU).
    Difference
    5%
    Check dated 2024-02-16T21:20:09.000Z thumbnail image
  9. Check
    25 days ago
    Change Detected
    Summary
    Important update:The recent change on the webpage indicates that Regeneron has announced their investor conference presentations on February 6th.
    Difference
    2%
    Check dated 2024-02-07T11:27:33.000Z thumbnail image
  10. Check
    29 days ago
    Change Detected
    Summary
    Important update:The value on the webpage has recently changed to "Feb 2 Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results" and "Feb 2 Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma." This change represents the announcement of Regeneron's financial and operating results for the fourth quarter and full year of 2023, as well as the acceptance of Linvoseltamab by the European Medicines Agency for the treatment of relapsed/refractory multiple myeloma.
    Difference
    9%
    Check dated 2024-02-03T09:32:26.000Z thumbnail image
  11. Check
    32 days ago
    Change Detected
    Summary
    Important update:The value on the webpage has changed to "Jan 30 Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs." This change represents an announcement by Regeneron Pharmaceuticals regarding the formation of Regeneron Cell Medicines through the acquisition of 2seventy bio Platforms and related programs.
    Difference
    8%
    Check dated 2024-01-31T06:58:35.000Z thumbnail image

Stay in the know with updates to Regeneron Pharmaceuticals Press Releases

Enter your email address, and we'll notify you when there's something new on the Regeneron Pharmaceuticals Press Releases page.